6-KThe Wire
Sanofi files 6-K
Filed Jun 8, 2026 · 25d ago · Accession 0001193125-26-260613
Plain English
Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for venglustat, a potential treatment for type 3 Gaucher disease. This filing is a report of foreign private issuer for the month of June 2026.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- Jun 8, 2026
- Report date
- Jun 8, 2026
- Document
- d123884d6k.htm
- Size
- 34 KB